Literature DB >> 10395708

Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance.

K Ina1, J Itoh, K Fukushima, K Kusugami, T Yamaguchi, K Kyokane, A Imada, D G Binion, A Musso, G A West, G M Dobrea, T S McCormick, E G Lapetina, A D Levine, C A Ottaway, C Fiocchi.   

Abstract

Crohn's disease (CD) is a condition characterized by excessive numbers of activated T cells in the mucosa. We investigated whether a defect in apoptosis could prolong T cell survival and contribute to their accumulation in the mucosa. Apoptotic, Bcl-2+, and Bax+ cells in tissue sections were detected by the TUNEL method and immunohistochemistry. T cell apoptosis was induced by IL-2 deprivation, Fas Ag ligation, and exposure to TNF-alpha and nitric oxide. TUNEL+ leukocytes were few in control, CD, and ulcerative colitis (UC) mucosa, with occasional CD68+ and myeloperoxidase+, but no CD45RO+, apoptotic cells. Compared with control and UC, CD T cells grew remarkably more in response to IL-2 and were significantly more resistant to IL-2 deprivation-induced apoptosis. CD T cells were also more resistant to Fas- and nitric oxide-mediated apoptosis, whereas TNF-alpha failed to induce cell death in all groups. Compared with control, CD mucosa contained similar numbers of Bcl-2+, but fewer Bax+, cells, while UC mucosa contained fewer Bcl-2+, but more Bax+, cells. Hence, the Bcl-2/Bax ratio was significantly higher in CD and lower in UC. These results indicate that CD may represent a disorder where the rate of T cell proliferation exceeds that of cell death. Insufficient T cell apoptosis may interfere with clonal deletion and maintenance of tolerance, and result in inappropriate T cell accumulation contributing to chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10395708

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  86 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Life and death in the gut: more killing, less Crohn's.

Authors:  A Sturm; C Fiocchi
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

3.  Inflammatory Bowel Disease: Future Therapies.

Authors:  Sander J.H. Van Deventer
Journal:  Curr Treat Options Gastroenterol       Date:  2002-06

4.  Specific targeting of IL-6 signalling pathway: a new way to treat IBD?

Authors:  P Desreumaux
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

5.  Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

Authors:  N Borruel; M Carol; F Casellas; M Antolín; F de Lara; E Espín; J Naval; F Guarner; J R Malagelada
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

6.  Anti-tumour necrosis factor therapy in Crohn's disease: where are we now?

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

7.  Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis.

Authors:  A Sturm; A Z A Leite; S Danese; K A Krivacic; G A West; S Mohr; J W Jacobberger; C Fiocchi
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

Review 8.  T cell apoptosis and inflammatory bowel disease.

Authors:  M P Peppelenbosch; S J H van Deventer
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

Review 9.  CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts.

Authors:  J Sträter; P Möller
Journal:  Virchows Arch       Date:  2003-02-11       Impact factor: 4.064

10.  Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease.

Authors:  A Di Sabatino; R Ciccocioppo; B Cinque; D Millimaggi; R Morera; L Ricevuti; M G Cifone; G R Corazza
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.